Istituti Clinici Scientifici Maugeri
Milan, Milano, 20138, Italy
NCT Number: NCT05733494
The English version of the "Clinical Assessment of Dysphagia in Neurodegeneration" (CADN), represents a rapid and valid clinical assessment tool for dysphagia in neurodegenerative population.
Currently, there is no validated tool in Italian specific for the clinical assessment of dysphagia in neurodegenerative disease with strong psychometric characteristics.
The present study aims to translate and validate the Italian version of CADN in neurodegenerative population. Psychometric properties will be measured.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Milan, Milano, 20138, Italy
Most of patients with a neurodegenerative disease will develop swallowing impairments (dysphagia) during their disease progression (up to 80%- 100% in Parkinson disease and Amyotrophic Lateral Sclerosis).
Dysphagia is associated with serious clinical complications, particularly regarding loss of life quality, insufficient medication intake, malnutrition, dehydration, and aspiration with subsequent pneumonia, which is the leading cause of death in this population.
Early detection and measurement of dysphagia trough validated and standardized procedures plays a fundamental role in the clinical practice. Clinical assessment by a speech language pathologist (SLP) can provide early identification of dysphagia and its severity and direct clinical decision making.
The English version of the "Clinical Assessment of Dysphagia in Neurodegeneration" (CADN), represents a rapid and valid clinical assessment tool for dysphagia in neurodegenerative population.
Currently, there is no validated tool in Italian specific for the clinical assessment of dysphagia in neurodegenerative disease with strong psychometric characteristics.
The present study aims to translate and validate the Italian version of CADN in neurodegenerative population.
The study will be carried out in two phases:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
the CADN will be administrated to each patient at the enrolment
Time frame: at the enrolment
Clinical assessment tool administrated by a Speech Language Pathologist. The CADN is composed by a clinical case history and a consumption part for a total of 11 item. Severity scores for each item range from 0 (no impairment) to 4 (severe impairment).
Time frame: at 24 hours from enrolment
Clinical assessment tool administrated by a Speech Language Pathologist. The CADN is composed by a clinical case history and a consumption part for a total of 11 item. Severity scores for each item range from 0 (no impairment) to 4 (severe impairment).
Time frame: At the enrolment
Instrumental examination, gold standard for the assessment of dysphagia.
Istituti Clinici Scientifici Maugeri SpA
Other
Cross-Cultural Adaptation and Validation of the Italian Version of the Clinical Assessment of Dysphagia in Neurodegeneration (CADN)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04584658
COVID-19, Coronaviridae Infections
Cambridge, United Kingdom
View Trial DetailsNCT06288243
Brain Diseases, Cardiovascular Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT05832658
Biofeedback, Brain Diseases
Kocaeli, Turkey (Türkiye)
View Trial DetailsNCT05678686
Brain Diseases, Cardiovascular Diseases
Konya, Selcuklu, Turkey (Türkiye)
View Trial Details